Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
OBJECTIVE
To review the clinical trials evaluating the efficacy of etidronate and alendronate in the treatment of established postmenopausal osteoporosis.


METHODS
A MEDLINE search was performed (from 1966 through September 1998) using the search terms bisphosphonates, etidronate, alendronate, and postmenopausal osteoporosis. English-language articles were considered for review.


METHODS
Prospective, randomized, double-blind, placebo-controlled clinical trials using fracture as an end point were selected to review the efficacy of etidronate and alendronate in the treatment of postmenopausal osteoporosis. Results for the outcomes of bone mineral density (BMD) and fracture are summarized.


RESULTS
Etidronate and alendronate increase spinal BMD in postmenopausal women with osteoporosis. In one study, etidronate decreased the number of women sustaining new radiographic vertebral fractures over two years, but this effect was lost after three years of treatment. Alendronate reduces the number of radiographic vertebral fractures in postmenopausal women with a low bone mass. In women with preexisting fractures, alendronate decreases the number of patients with radiographic vertebral fractures, clinical (i.e., symptomatic vertebral and nonvertebral) fractures, and hip fractures. A significant reduction in the overall number of nonvertebral fractures has not been demonstrated in clinical trials evaluating either alendronate or etidronate.


CONCLUSIONS
No studies have directly compared the efficacy of alendronate and etidronate and the results of long-term clinical trials (i.e., >5 y) have not been published. Based on the results obtained in clinical trials using fracture as an end point, alendronate appears to be the bisphosphonate of choice. Safety profiles and cost should also be considered in the choice of etidronate or alendronate for the treatment of postmenopausal osteoporosis.
Beauchesne
M F
MF
Pharmacy Department, Sacré-Coeur Hospital, Montréal, Québec, Canada.
Miller
P F
PF
D000375:Aging; D019386:Alendronate / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015519:Bone Density / Q000502:physiology*; D002986:Clinical Trials as Topic; D003625:Data Collection; D012968:Etidronic Acid / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000188:drug therapy / Q000191:economics / Q000209:etiology*; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000191:economics
D012968:Etidronic Acid; D019386:Alendronate